Ignite Creation Date:
2024-05-06 @ 10:37 AM
Last Modification Date:
2024-10-26 @ 12:33 PM
Study NCT ID:
NCT03310372
Status:
COMPLETED
Last Update Posted:
2017-10-17
First Post:
2017-10-11
Brief Title:
Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Phase II Clinical Trial of Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEMOFRAC
Brief Summary:
The main purpose of this study is the evaluation of concomitant association of ultrafractionated irradiation and Temodal in patients with inoperable primary glioblastoma multiforme study of tolerance and objective response rate
The secondary purposes of this study are the evaluation of progression free survival global survival and tolerance through toxicity study The therapeutic response according to methylation or not of MGMT is also evaluated
The secondary purposes of this study are the evaluation of progression free survival global survival and tolerance through toxicity study The therapeutic response according to methylation or not of MGMT is also evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None